Benzodiazepines and Z-hypnotics consumption in long-COVID-19 patients: Gender differences and associated factors
Resumen
Background: Psychotropic drug consumption has increased during the COVID-19 pandemic. We describe here the prevalence and identifying factors associated with Benzodiazepine (BZD) and Z-hypnotics use among a sample of Spanish adults suffering from long-COVID-19 syndrome, from a gender perspective. Materials and methods: Data were anonymously collected between 15th December 2021 and 15th March 2022. The collection form consisted of several questions gathering sociodemographic information, post-COVID symptom, health profile, and pharmacological drug intake. Using logistic multivariate regression models, we estimated the independent effect of each of these variables on self-medicated consumption. Three models were generated (female, male, and both gender). Results: Prevalence of BZD and Z-hypnotics use was 44.9% (46.5% for women; 37.8% for men). Zolpidem was the most consumed drug among male (20.7%), and lorazepam in female (31.1%). Patterns of drug consumption among female were related with number of post-COVID symptoms and smoking habit (AOR 2.76, 95%CI 1.16-6.52). Males under 40 years of age are more likely to consume BZD and Z-hypnotics (AOR 5.52, 95%CI 1.08-28.27). Conclusion: The prevalence of consumption of BZD and Z-hypnotics in those subjects with long-COVID-19 in our study reaches values of 44.9%. Women with long-COVID-19 declare a higher prevalence of consumption than men. Predictors of BZD and Z-hypnotic in men were, age and number of medication use. Smoking habit and the number of post-COVID symptoms were predictive variables in women.
Descripción
Publicación científica en revista indexada con índice de calidad relativo, incluida en los catálogos del Journal Citation Reports (JCR). La revista científica Frontiers in Medicine pertenece y al segundo cuartil (Q2) de su categoría Medicine, General & Internal (SCIE): 58/177. Factor de Impacto en el año 2022: 3.9 https://pubmed.ncbi.nlm.nih.gov/36160133/#full-view-affiliation-2 Este artículo deriva de un Proyecto de Investigación The Long Covid Experience Study. Evolución, Caracterización Clínica, Molecular y Genética y Tratamiento de los Síntomas post-COVID (COVID Persistente) financiado por la Comunidad de Madrid y la Unión Europea, a través del Fondo Europeo de Desarrollo Regional (FEDER), Recursos REACT-UE del Programa Operativo de Madrid 2014-2020, financiado como parte de la respuesta de la Unión Europea a la pandemia de COVID-19 (LONG-COVID-EXP-CM). Investigadora Principal del Subproyecto 6 “Perfil fármaco-epidemiológico del paciente con COVID persistente” : Pilar Carrasco Garrido. https://www.longcovid.eu/subproyecto-6-perfil-farmaco-epidemiologico/
Colecciones
- Artículos de Revista [4166]